Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL
← catalyst calendarNCT05147467 · readout ≤ 134 d
Sponsored by Ascentage Pharma Group Inc. (industry) · AAPG — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
75estimated
Sites
11
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-12-28 | actual | When the study began enrolling |
| Primary completion | Dec 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2021-12-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
Intervention
- Drug: APG2575
Primary outcome
what the primary-completion date above is the date OFObjective Response Rate (ORR)
measured Up to 9 months after the last subject enrolled.
Permalink · AAPG's whole pipeline · Catalyst calendar · Every registered study · What changed